Zhejiang Orient Gene Biotech's (SHA:688298) subsidiaries received medical device registration certificates for three detection kits, according to a Shanghai Stock Exchange disclosure on Wednesday.
The devices are hepatitis B virus nucleic acid detection kit (fluorescence PCR method), and pepsinogen I and II detection kits (time-resolved fluorescence immunochromatography).
The certificate for hepatitis B kit is valid until Dec. 29, 2029, while those for the pepsinogen kits are valid until Dec. 23, 2029, the disclosure added.
Shares of the company closed over 3% lower.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。